Skip to main content

Search

Reset all filters
859 Result(s)
Sort by

Update on LUME-Meso Clinical Trial

Update on LUME-Meso Clinical Trial

Click here to read an update on the LUME-Meso clinical trial, comparing nintedanib with other treatment options for malignant pleural mesothelioma.
Matthias Muenks

Matthias Muenks

Matthias Muenks, Global Engineering Process and Data Manager at Boehringer Ingelheim, speaks about the pharmaceutical company’s innovation and culture.
Benefits & Rewards

Benefits & Rewards

We invest in our people so they will stay and grow with us. We offer benefits such as rewards and development opportunities to help retain employees.
Animal Health: Our Responsibility

Animal Health: Our Responsibility

BI's commitment to animal health is reflected in our more than 100 years of successful company history. It is also at the core of sustainability.
FDA approved treatment option for adults with CKD

FDA approved treatment option for adults with CKD

The FDA has approved Jardiance® (empagliflozin) tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with CKD at risk of progression.
Dirk Stenkamp

Dirk Stenkamp

Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
Edda Dankmeyer

Edda Dankmeyer

Edda Dankmeyer leads Sustainable Development Communications and explains how sustainable development can bea key differentiator for the company.
Respiratory Diseases

Respiratory Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Immunology

Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
Technologies

Technologies

We are expanding our global network of technology partners. Learn more about partnering with us.